A.C.T.H in Nephrosis

Arneil, Gavin C.; Wilson, H. E. C.

doi:10.1136/adc.28.141.372

Cited by 23 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and cortisone but stated that they were short-lived and that recurrences were frequent. Arneil andWilson (1952, 1953) confirmed the diuretic effect of A.C.T.H. and cortisone but considered that these hormones were of limited value.…”

Section: Treatmentmentioning

confidence: 93%

The Natural History of Nephrosis

Rm¹

1957

Archives of Disease in Childhood

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 93%

The Natural History of Nephrosis

Rm¹

1957

Archives of Disease in Childhood

View full text Add to dashboard Cite

“…It has been known for a long time that melanocortin peptides possess a significant effect in the kidney 30 . As a matter of fact, ACTH has been used since a half century ago for the treatment of nephrotic glomerular disease 31 . In addition, the kidney protective activity possessed by melanocortins, in particular α-MSH and ACTH, has been reproducibly demonstrated in multiple animal models of kidney diseases, including MN 32 , FSGS 33 , acute kidney injury (AKI) due to ischemia or sepsis 26,28 , renal toxicity 34 and ureteral obstruction 27,35 .…”

Section: Kidney Is An Important Effector Organ Of the Melanocortin Homentioning

confidence: 99%

“…As one of the 4 native melanocortin peptides, ACTH has been widely used since early 1950s for the treatment of nephrotic syndrome possibly caused by lipoid nephrosis, an older term for nil lesion or MCD 31,69,70 . ACTH therapy was particularly provided for childhood nephrotic syndrome in lieu of steroids with the hope of less growth retardation since it does not suppress the adrenal glands 31 .…”

Section: Melanocortin Based Therapy For Glomerular Diseases: Clinicalmentioning

confidence: 99%

Leveraging Melanocortin Pathways to Treat Glomerular Diseases

Gong

2014

Advances in Chronic Kidney Disease

View full text Add to dashboard Cite

The melanocortin system is a neuroimmunoendocrine hormone system that constitutes the fulcrum in the homeostatic control of a diverse array of physiological functions, including melanogenesis, inflammation, immunomodulation, adrenocortical steroidogenesis, hemodynamics, natriuresis, energy homeostasis, sexual function and exocrine secretion. The kidney is a quintessential effector organ of the melanocortin hormone system with melanocortin receptors abundantly expressed by multiple renal paranchymal cells, including podocytes, mesangial cells, glomerular endothelial cells and renal tubular cells. Converging evidence unequivocally demonstrates that the melanocortin based therapy by using the melanocortin peptide adrenocorticotropic hormone (ACTH) is prominently effective in inducing remission of steroid resistant nephrotic syndrome caused by a variety of glomerular diseases, including membranous nephropathy and podocytopathies such as minimal change disease and focal segmental glomerulosclerosis, suggesting a steroidogenic independent melanocortin mechanism. Mechanistically, ACTH and other melanocortin peptides as well as synthetic melanocortin analogues possess potent proteinuria reducing and renoprotective effects that could be attributable to both direct protection of glomerular cells and systemic immunomodulation. Thus, leveraging melanocortin signaling pathways by using either the existing U.S. Food and Drug Administration approved melanocorin peptide ACTH or novel synthetic melanocortin analogues represents a promising and pragmatic therapeutic strategy for glomerular diseases. This review article introduces the biophysiology of melanocortin hormone system with emphasis on the kidney as the target organ, discusses the existing clinical and experimental data on melanocortin treatments for glomerular diseases, elucidates the potential mechanisms of action, and describes the potential side effects of melanocortin based therapy.

show abstract

“…Hypo electrolyte mia, convulsions, and increased risk of infections constitute the major hazards of hormone therapy (105,121,122,123). Impaired renal func tion or sustained hypertension probably contraindicate prolonged or re peated courses (123).…”

Section: Renal Diseasementioning

confidence: 99%

Pediatrics

Platou¹

1956

Annu. Rev. Med.

View full text Add to dashboard Cite

A.C.T.H in Nephrosis

Cited by 23 publications

References 14 publications

The Natural History of Nephrosis

The Natural History of Nephrosis

Leveraging Melanocortin Pathways to Treat Glomerular Diseases

Pediatrics

Contact Info

Product

Resources

About